• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BioDelivery reacquires license to buprenorphine film

December 8, 2016 By Sarah Faulkner

BioDelivery reacquires license to buprenorphine film

BioDelivery Sciences International (NSDQ:BDSI) said today that it reacquired the license to the Belbuca (buprenorphine) buccal film from Endo Pharmaceuticals. Malvern, Penn-based Endo Pharmaceuticals licensed the worldwide manufacturing and marketing rights to the opioid patch from BioDelivery in 2012.

Belbuca, a once-daily opioid, is indicated for the management of severe pain. The small, peppermint-flavored film works by sticking to the cheek and dissolving within 30 minutes.  Projections show that Belbuca gross sales will exceed $27 million, according to Raleigh, N.C.-based BioDelivery.

“We respect Endo’s strategic decision regarding its U.S. branded pain portfolio and appreciate its role in bringing Belbuca to the market,” BioDelivery’s president & CEO Mark Sirgo said in prepared remarks.  “While this change in direction is not what we originally envisioned for Belbuca, Endo has laid a significant foundation for Belbuca, and in so doing, has created a significant opportunity for BDSI. We recognize the hard work put forth by both companies since we entered our licensing and development agreement in 2012, and we appreciate the exceptional working relationship that has existed. We look forward to Endo’s support behind the upcoming transition.”

“We believe Belbuca is well positioned to provide healthcare providers and their patients a responsible solution for the treatment of chronic pain while also addressing the widespread concerns over the growing problem of opioid abuse, addiction and overdose in this country,” he added. “Belbuca provides important patient benefits and is well differentiated from other opioids. And as such, we believe Belbuca has promising growth potential and the ability to add tremendous value to our company.”

Filed Under: Featured, Pain Management, Sublingual films, Wall Street Beat Tagged With: BioDelivery Sciences International, Endo Pharmaceuticals

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS